This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-07-0197v1 16/11/2218    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flick, E. D. Articles by Caan, B. J. Search for Related Content PubMed PubMed Citation Articles by Flick, E. D. Articles by Caan, B. J. Related Collections Commentary

Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort

¹ Division of Research, Kaiser Permanente, Northern California; ² Department of Research and Evaluation, Kaiser Permanente, Southern California; ³ Department of Epidemiology, Harvard School of Public Health, ⁴ Division of General Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and ⁵ i3 Drug Safety, Waltham, Massachusetts

Requests for reprints: E. Dawn Flick, Division of Research, Kaiser Permanente, 2000 Broadway, 5th Floor, Oakland, CA 94612. Phone: 510-891-3103; Fax: 510-891-3761. E-mail: eflick{at}post.harvard.edu

Statins have known anticarcinogenic effects, however, evidence for long-term statin use as effective chemoprevention for prostate cancer is inconsistent. We examined the association between statin use and risk of prostate cancer among 69,047 eligible participants in the California Men's Health Study, a prospective cohort of Northern and Southern California Kaiser Permanente (KP) members, ages 45 to 69 years, initiated in 2002. Prostate cancer cases were identified by linkage to the KP California Cancer Registries. Statin exposure, estimated from automated KP outpatient pharmacy records (available since 1991 in Southern California and since 1994 in Northern California), was treated as time-varying and defined as the cumulative days dispensed of any statin from the first dispensing until a prostate cancer diagnosis, radical prostatectomy, termination of membership, or end of study (December 31, 2004). Cox proportional hazards models with age as the time scale were used to estimate rate ratios, while controlling for confounding variables. During follow-up, 888 prostate cancer cases, including 131 advanced cases, were identified. There was no association between ever statin use or <5 years use and prostate cancer. Conversely, 5 years use was associated with a 28% lower risk for prostate cancer compared with nonuse (adjusted rate ratio, 0.72; 95% confidence interval, 0.53-0.99). This association did not differ markedly for advanced disease. However, the association did seem to be restricted to those who regularly take nonsteroidal anti-inflammatory drugs. Our findings suggest that long-term statin use might be associated with a reduced risk of prostate cancer but perhaps only among regular nonsteroidal anti-inflammatory drug users. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2218–25)

Commentary

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Elizabeth A. Platz
Cancer Epidemiol. Biomarkers Prev. 2007 16: 2175-2180. [Full Text] [PDF]

This article has been cited by other articles:

				I. Agalliu, C. A. Salinas, P. D. Hansten, E. A. Ostrander, and J. L. Stanford Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study Am. J. Epidemiol., June 12, 2008; (2008) kwn141v1. [Abstract] [Full Text] [PDF]

				E. A. Platz Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2175 - 2180. [Full Text] [PDF]